Promising vasculitis drug trial halted early

NCT ID NCT05376319

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two drugs, obinutuzumab and rituximab, for treating a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal was to see if obinutuzumab could help more patients achieve remission and clear disease markers. However, the trial was stopped early after enrolling only 6 people, so we cannot draw meaningful conclusions about which drug works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obinutuzumab
What this could lead to: If it had worked, obinutuzumab might have offered a new treatment option for controlling vasculitis, potentially leading to remission with fewer relapses.
What could go wrong: The trial was terminated early with only 6 participants, so no reliable conclusions can be drawn. The drug may not be more effective than rituximab and could have similar or new side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis granulomatosis with polyangiitis microscopic polyangiitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA-ASSOCIATED VASCULITIS GRANULOMATOSIS WITH POLYANGIITIS MICROSCOPIC POLYANGIITIS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.